Sigyn Therapeutics (SIGY) Non Operating Interest Expenses (2016 - 2021)

Sigyn Therapeutics has disclosed Non Operating Interest Expenses across 6 years of filings, most recently posting $22260.0 for Q2 2021.

• In Q2 2021, Non Operating Interest Expenses rose 155.1% year-over-year to $22260.0; the TTM figure through Jun 2021 stood at $194021.0 (up 112.91% YoY), while the FY2020 annual figure was $343156.0, up 521.66% from the prior year.
• Non Operating Interest Expenses came in at $22260.0 for Q2 2021 at Sigyn Therapeutics, up from $8726.0 in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $453231.0 in Q4 2017 to a low of $8350.0 in Q4 2019.
• Average Non Operating Interest Expenses over 5 years is $86913.1, with a median of $53380.0 recorded in 2018.
• Year-over-year, Non Operating Interest Expenses sank 89.29% in 2018 and surged 1748.01% in 2020.
• Over 5 years, Non Operating Interest Expenses stood at $453231.0 in 2017, then slumped by 89.29% to $48557.0 in 2018, then slumped by 82.8% to $8350.0 in 2019, then surged by 1748.01% to $154309.0 in 2020, then slumped by 85.57% to $22260.0 in 2021.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $22260.0 in Q2 2021, $8726.0 in Q1 2021, and $154309.0 in Q4 2020.